Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

PurposeWe aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC).MethodsPatients with initially unresectable HCC who received combined lenvatinib and anti-PD-1 antibody between May 2020 and Jan 2022...

Description complète

Détails bibliographiques

Auteurs principaux:	Yong Yi, Bao-Ye Sun, Jia-Lei Weng, Cheng Zhou, Chen-Hao Zhou, Ming-Hao Cai, Jing-Yun Zhang, Hong Gao, Jian Sun, Jian Zhou, Jia Fan, Ning Ren, Shuang-Jian Qiu
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2022-11-01
Collection:	Frontiers in Oncology
Sujets:	hepatocellular carcinoma lenvatinib Anti-PD-1 therapy conversion resection objective response
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1046584/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!